CLINICAL_TRIALS
trial_result
· 2026-03-06
Clinical Trial Update: An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer [Phase 2]
Summary
A Phase 2 adjuvant trial evaluating SMS001 (paclitaxel) for non-small cell lung cancer is currently recruiting.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: ToLymph Inc. | Conditions: Carcinoma, Non-Small-Cell Lung Cancer (NSCLC) | Phase 2 | Status: RECRUITING